A study of motivations/expectations of patients seen in phase 1 oncology clinics - Roayl Marsden Hospital UK Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, September 26, 2016

A study of motivations/expectations of patients seen in phase 1 oncology clinics - Roayl Marsden Hospital UK

 This study was previously presented at the American Society of Clinical Oncology Congress; June 3-7, 2016; Chicago, IL, Abstract no 10061
We thank the patients who participated in this study and their families, the Royal Marsden patient advocacy group, Debarati Goswami, and Kirsty Moran.


To better inform clinical practice, this study was aimed at capturing patients' motivations for enrolling in phase 1 trials and at quantifying their expectations of the benefits, risks, and commitment associated with clinical trials and the impact of the initial consultation on their expectations.


This was a single-center, prospective, quantitative study of newly referred adult patients considering their first phase 1 oncology trial. Participants completed questionnaires before they were seen and an abbreviated follow-up version after their consultation.

Patient Characteristics

Between September 2012 and March 2015, questionnaires were given to 402 prospective adult patients at their first attendance in the new patient phase 1 clinic of the Drug Development Unit. Ninety nine percent (n = 396) gave written consent to participate and completed the preclinic questionnaire; 301 patients returned the postclinic questionnaire (76%). The mean age was 57.4 years (standard deviation, 12.9 years); there was a slight preponderance of females (56.3%), and there was an even distribution of participants leaving formal education before and after the age of 17 years (46.2 vs 44.7%; Table 1). The commonest cancers were gastrointestinal, gynecological, and lung cancers, with their respective cancer specialists being the major primary referrers for 87.1% of the patients (Table 1).

Cancer site, No. (%)

Breast40 (10.1)
Gastrointestinal153 (38.6)
Gynecological66 (16.7)
Lung58 (14.6)
All others79 (19.9)              Total 396 (100.00)


Post a Comment

Your comments?